Patents by Inventor Jonah B. SACHA

Jonah B. SACHA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEPATITIS B VIRUS-SPECIFIC T CELL RESPONSES
    Publication number: 20220257748
    Abstract: The present disclosure relates to methods to generate an immune response for the treatment or prevention of hepatitis B virus infection. This disclosure also relates to methods to generate MHC-E and/or MHC-II restricted CD8+ T cells for the treatment or prevention of hepatitis B virus infection.
    Type: Application
    Filed: June 5, 2020
    Publication date: August 18, 2022
    Inventors: Klaus J. FRÜH, Louis J. PICKER, Benjamin J. BURWITZ, Scott G. HANSEN, Jonah B. SACHA
  • Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
    Patent number: 10981976
    Abstract: The present invention features anti-HERV-K monoclonal antibodies or antigen-binding portions thereof. The present invention also features uses of the antibodies for treating HIV infection or HIV-associated conditions or diseases.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: April 20, 2021
    Assignees: University of Rochester, Oregon Health & Science University, George Washington University
    Inventors: James J. Kobie, Jonah B. Sacha, Douglas F. Nixon
  • USE OF BISPHOSPHONATES AS HIV/AIDS ADJUNCTIVE TREATMENT
    Publication number: 20180064733
    Abstract: The present invention relates to use of bisphosphonate formulations for the treatment and management of HIV/AIDS. The method of the invention comprises administering a formulation comprising an effective amount of a bisphosphonate that specifically inhibits the activity and/or decreases the number of monocytes and/or macrophages, thereby reducing or eliminating HIV reservoirs. The invention also provides a method of complementing an HIV antiviral therapy, such as the highly active antiretroviral therapy (HAART), with a bisphosphonate formulation to improve clinical outcome.
    Type: Application
    Filed: October 13, 2017
    Publication date: March 8, 2018
    Inventors: Yoram RICHTER, Gershon GOLOMB, Jonah B. SACHA
  • Use of bisphosphonates as HIV/AIDS adjunctive treatment
    Patent number: 9820998
    Abstract: The present invention relates to use of bisphosphonate formulations for the treatment and management of HIV/AIDS. The method of the invention comprises administering a formulation comprising an effective amount of a bisphosphonate that specifically inhibits the activity and/or decreases the number of monocytes and/or macrophages, thereby reducing or eliminating HIV reservoirs. The invention also provides a method of complementing an HIV antiviral therapy, such as the highly active antiretroviral therapy (HAART), with a bisphosphonate formulation to improve clinical outcome.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: November 21, 2017
    Assignees: BIOREST LTD., OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Yoram Richter, Gershon Golomb, Jonah B. Sacha
  • USE OF BISPHOSPHONATES AS HIV/AIDS ADJUNCTIVE TREATMENT
    Publication number: 20150328237
    Abstract: The present invention relates to use of bisphosphonate formulations for the treatment and management of HIV/AIDS. The method of the invention comprises administering a formulation comprising an effective amount of a bisphosphonate that specifically inhibits the activity and/or decreases the number of monocytes and/or macrophages, thereby reducing or eliminating HIV reservoirs. The invention also provides a method of complementing an HIV antiviral therapy, such as the highly active antiretroviral therapy (HAART), with a bisphosphonate formulation to improve clinical outcome.
    Type: Application
    Filed: May 15, 2015
    Publication date: November 19, 2015
    Inventors: Yoram RICHTER, Gershon GOLOMB, Jonah B. SACHA